MEDIPOST obtained a patent in Japan for its core technology that uses cord blood stem cells for treating Alzheimer’s disease.

This patented technology induces the damaged cranial nerve cells to regenerate.

MEDIPOST plans to use this technology for the currently being developed Alzheimer’s disease drug, NEUROSTEM^®.

This patent is currently registered in China, Hong Kong, Singapore, UK, Germany, France, Italy, Spain, Switzerland, Australia, Mexico as well as in Korea.